Zevra Therapeutics, Inc. ZVRA Debt Instrument, Unamortized Discount (Premium), Net

Debt Instrument, Unamortized Discount (Premium), Net at other companies

MSCIMSCI

$51.4M+78.5%

The Travelers CompaniesTRV

$118M+12.4%

General DynamicsGD

$58M-15.9%

Rockwell AutomationROK

$26M-23.5%

Main Street CapitalMAIN

$13.05M+11.8%

Warrior Met CoalHCC

$2.1M-23.8%

Other financials

Income statement

See full

Revenue$36.2M+77.5%

Gross profit$34.3M+80.1%

Operating income$52.1M+1,073%

Net income$37.9M+1,323%

EPS (diluted)$0.60+1,100%

Balance sheet

See full

Cash & equivalents$95.6M+156%

Total debt$1.1M-98.1%

Total equity$205.8M+402%

Total assets$278.6M+61.3%

Cash flow

See full

Operating cash flow$6.1M+175%

CapEx$35.0K-64.6%

Free cash flow$6.1M+173%

Valuation

See full

Market cap$782.09M+58.2%

Enterprise value$687.64M+32.5%

P/E6.3×—

P/S6.4×-5.8×

Profitability

See full

Gross margin86.1%+7.2pp

Operating margin-103.9%-43.0pp

Net margin101.6%+60.1pp

FCF margin-75%-30.5pp

Returns & leverage

See full

Return on equity100.7%+60.3pp

Debt / equity0×-1.5×

Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s debt instrument, unamortized discount (premium), net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s debt instrument, unamortized discount (premium), net?: Zevra Therapeutics, Inc. (ZVRA) reported debt instrument, unamortized discount (premium), net of $755K in Q4 2025.